drugset / Trial / NCT05691153
ThisCART19A for B-NHL Relapsed After Auto-CAR T
Phase 1
Unknown
20 enrolled
The First Affiliated Hospital of Soochow University
Fundamenta Therapeutics, Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART19A | Cell therapy | 2 cells/kg | Intravenous |
| Subject | ThisCART19A | Cell therapy | 3 cells/kg | Intravenous |